Fig. 5: P53 is the key to beraprost-mediated effect on bone mass.
From: Beraprost ameliorates postmenopausal osteoporosis by regulating Nedd4-induced Runx2 ubiquitination
A, B Volcano plots and heatmap of genes with significant changes in beraprost-stimulated M-BMSCs. C KEGG pathway analysis indicating altered function of the PI3K–AKT pathway. D GSEA showing that processes involved in negative regulation of protein modification were affected. E Western blot analysis of the transfection efficiency of p53 in M-BMSCs. F Quantitative analysis of ALP activity. n = 5; **P < 0.01, ***P < 0.001 by ANOVA with Tukey’s post-hoc test. G Quantitative RT-PCR of mRNA expression of Runx2, Alp, OCN, OSX, and Nedd4 in M-BMSCs. Results are shown as mean ± SD; n = 5; *P < 0.05, **P < 0.01, and ***P < 0.001 by ANOVA with Tukey’s post-hoc test. H Western blotting images of protein expression of pI3k, p-pI3k, AKT, p-AKT, mdm2, and p53 in M-BMSCs. I Representative images of ALP and ARS staining. J Western blot images showing protein expression of p53 in WT and p53 knockout mice. K Images of gene identification by DNA electrophoresis. L Representative images of micro-CT reconstruction of distal femurs. M Histomorphometric analysis of the distal femurs. Results are shown as mean ± SD; n = 5; *P < 0.05, **P < 0.01, and ***P < 0.001 by ANOVA with Tukey’s post-hoc test.
